Naoko Takebe

Oklahoma State University Oklahoma City — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

50h-index12.0kcitations651works0.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(98), Glioma Diagnosis and Treatment(93), Cancer Genomics and Diagnostics(56), Click Chemistry and Applications(52), Hedgehog Signaling Pathway Studies(49)

Publications651 total

Patient Blood Management in Cancer Surgery

International Anesthesiology Clinics·2026

Supplementary Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Table 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Data from Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000–2023): A Cohort Study

2025Open Access

Supplementary Figure 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Table 3 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Supplementary Table 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Supplementary Figures 1-5 from Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000–2023): A Cohort Study

2025Open Access

Figure 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Figure 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Data from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

2025Open Access

Synergy between photonics and biological approaches—A review of combination therapies for cancer theranostics

APL Bioengineering·2025Open Access

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Cancer Research Communications·2025Open Access

Figure S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

Table S4 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

Table S6 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

Table S5 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

Figure S13 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

2025Open Access

page 1 of 33Next →

Frequent Co-authors

Alice P. Chen(8), James H. Doroshow(7), S. Percy Ivy(6), P. Mickey Williams(5), James V. Tricoli(5), Geraldine O’Sullivan Coyne(5), Lisa M. McShane(4), David R. Patton(4), Brent Coffey(4), Larry Rubinstein(4), Richard F. Little(4), Barbara A. Conley(4), Abdul Rafeh Naqash(4), Lyndsay N. Harris(3), James A. Zwiebel(3), Margaret Mooney(3), Howard Streicher(3), Elad Sharon(3), Ralph E. Parchment(3), Y Tsunokawa(3)